Hypertrophic Scars Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

  • ID: 4451356
  • Report
  • 47 pages
  • P&S Market Research
1 of 3
Hypertrophic scars currently exhibits a growing pipeline with nine drug candidates.

Hypertrophic scars therapeutics pipeline in 2017

Body cells known as myofibroblasts produce excessive collagen during healing process which can be deposited as a bump and later changes to a hypertrophic scar. The study analyzed that the hypertrophic scars therapeutics pipeline comprises approximately nine drug candidates in different stages of development.

Insights on pipeline segments

Majority of the pipeline drug candidates are being developed to be administered by the topical route. SCX-001 cream has demonstrated anti-scarring effects in two in-vivo Pre-clinical dermal models. SCX-001 cream’s safety as a topical agent has also been confirmed in non-clinical Investigational New Drug (IND) in-vitro and in-vivo studies.

Specific targeted therapy expected to create opportunities for the pharmaceutical companies

The drug development process involves specific targets such as connective tissue growth factor inhibition which is the probable mechanism of action for the treatment of hypertrophic scars. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development.

Technological advancements enhancing the Pipeline Growth

Technological advancements have been strengthening the development of pipeline drugs for the treatment of hypertrophic scars. For instance, The RNA interference (RNAi) technology, was used in the development of OLX101 by OliX Pharmaceuticals, Inc.

Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.

Hypertrophic Scars Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Hypertrophic Scars Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Hypertrophic Scars Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase II: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase I: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Pre-Clinical: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology
5.4 Discontinued Drugs

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Hypertrophic Scars Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Hypertrophic Scars Therapeutics Pipeline

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Hypertrophic Scars Therapeutics Pipeline
7.2 SWOT Analysis Hypertrophic Scars Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Hypertrophic Scars Therapeutics, By Company (2017)
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
List Of Discontinued Drug Candidates
Companies - at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Hypertrophic Scars Therapeutics Drug Candidates Under Development (2017)
Hypertrophic Scars Pipeline Split, By Molecule Type (2017)
Hypertrophic Scars Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll